Cardiovascular disease detection provider Cardiosense raised USD 15.1 million in a venture funding round co-led by Hatteras Venture Partners and Broadview Ventures along with participation from other venture capital firms.

The raised funds will be used by the company to hire additional staff and speed up product development. The funds will also be used to carry out a clinical study on heart failure.

Post-funding the company will also appoint Jeff Terrell from Hatteras Venture Partners and Daniel Gottlieb from Broadview Ventures to the company’s board of directors.

Chicago-based Cardiosense is a developer of an AI-powered platform and devices used to identify predictive biomarkers that can help detect and manage heart disease. As of December 2022, the company has developed digital tools, multi-sensor devices, and an analysis algorithm for detecting early signs of cardiovascular disease, informing patient therapy, and improving patient outcomes. Cardiosense’s devices and platform currently focus on improving the management of congestive heart failure (CHF).